grants_govPAR-25-362
Open
Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
- Response deadline
- Nov 5, 2028 Due in 812 days
- Date posted
- Dec 30, 2024
- Source
- Open notice
Description
The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART).This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity.
Classifications
- NAICS93.865
Documents (1)
- DownloadPAR-25-362-Full-Announcement.htmltext/html422 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- Novel Experiential Technologies Assisting Individual Learning (NExT AI) Hubs (P20 Clinical Trial Optional)Due Oct 2, 2026
- Biological Testing Facility for Contraception & Reproductive Health (X01 Clinical Trial Not Allowed)Due May 7, 2029
- Limited Competition: Intellectual and Developmental Disabilities Research Centers 2027 (P50 Clinical Trial Optional)Due Oct 2, 2026
- Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional)Due Nov 15, 2027
- Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)Due Nov 16, 2027
- Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)Due Nov 16, 2027